Pearl Steinzor

AI could reduce administrative burden, improve diagnosis, and streamline prior authorization—but it could also fuel care cascades, upcoding, and unsustainable spending.

Sivelestat significantly reduced the incidence of postoperative ARDS, lowered 90-day mortality, and suppressed inflammatory biomarkers linked to lung injury.

Left bundle-branch pacing significantly lowered the combined risk of death or heart failure hospitalization compared with conventional biventricular pacing.

Intensive lifestyle programs for childhood obesity can prevent long-term chronic disease.

A Cleveland Clinic study shows a medically trained AI system can rapidly screen electronic health records to identify eligible participants for rare disease clinical trials.

A new study finds one-third of ambulatory patients with heart failure with reduced ejection fraction overestimate their life expectancy.

The approval is expected to offer more affordable treatment options and potentially reduce asthma-related complications nationwide.

A new science-focused autism committee mobilizes against controversial federal appointments.

National data reveal increasing rates of type 1 and type 2 diabetes among children insured through Medicaid and CHIP.

Clinical measures and biomarkers during pregnancy, including hs-cTnI and sFlt-1, can help identify women at higher risk of developing cardiovascular disease later in life.

Patients with oHCM experience significant variation in cardiovascular events, health care resource use, and costs across age, sex, race, and US region.

A Mississippi hospital partners with Eko Health to introduce AI-assisted cardiac detection in underserved rural communities.

Philip Mease, MD, shares how to individualize psoriatic disease treatment by weighing medication safety profiles, efficacy, and real-world lifestyle factors.

High area level housing cost burden is associated with increased cardiovascular hospitalizations and emergency department use among Medicaid beneficiaries.

Low-cost, scalable interventions can improve first-fill adherence, reduce avoidable hospitalizations, and support patient-centered strategies.

Orforglipron achieved greater A1C reduction and weight loss than oral semaglutide, highlighting its potential as a needle-free option for type 2 diabetes.

The ready-to-use formulation supports clinicians and families by addressing historical administration challenges.

As utilization of GLP-1s grows for diabetes and weight management, out-of-pocket expenses and affordability concerns may affect broader health care policy discussions.

Safety profiles, efficacy, and lifestyle factors inform shared decision-making and help optimize biologic selection in inflammatory disease management.

SGLT2 inhibitors were associated with significantly lower risks of kidney failure, cardiovascular events, mortality, and hepatic decompensation.

The number of brick and mortar abortion clinics in the US fell between 2024 and 2025, with notable closures even in states considered key access points.

The FDA will now review Moderna’s seasonal mRNA influenza vaccine application, setting a mid-2026 decision date.

New bipartisan legislation extends key health care programs and tightens oversight of PBMs in Medicare Part D and commercial markets, but impacts on drug costs will not be immediate.

Kohei Shitara, MD, discusses CLDN18.2-guided therapy, nivolumab plus zolbetuximab, and toxicity management in advanced gastric and gastroesophageal cancers.

Providing monthly produce prescriptions to patients with diabetes at risk for food insecurity did not significantly improve cardiometabolic parameters.

An analysis shows that oral semaglutide significantly lowers the risk of heart failure (HF) outcomes in patients with type 2 diabetes and a history of HF.

Longer diabetes duration was associated with a significantly increased risk of pancreatic cystic neoplasms.

Findings highlight strong overall performance but reveal variability among disaggregated Asian ethnic groups.

Meaningful reductions in all-cause mortality and cardiovascular hospitalizations modeled benefits compared with untreated populations.

The trial also showed significant reductions in non-HDL cholesterol, apolipoprotein B, and lipoprotein(a), with no apparent differences in adverse events between groups.